Sign In
Buy SLDB
$8.79
+0.490 (+5.90%)
At Close: Jun 23, 2026
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned
03:14pm, Wednesday, 11'th Mar 2026
Solid Biosciences Inc. (NASDAQ: SLDB) shares are tumbling on Wednesday following a recent update regarding the company's clinical trial for SGT-003, an investigational gene therapy.
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
01:01pm, Wednesday, 11'th Mar 2026
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
08:31am, Friday, 06'th Mar 2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, tod
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
08:30am, Friday, 06'th Mar 2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, tod
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Mar 2026
CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and c
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
06:17pm, Friday, 13'th Feb 2026
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
02:34am, Thursday, 12'th Feb 2026
Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) and Solid Biosciences (NASDAQ: SLDB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the tw
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
06:22pm, Monday, 09'th Feb 2026
Solid Biosciences maintains a 'Strong Buy' rating, driven by positive FDA alignment on the phase 3 IMPACT DUCHENNE trial for SGT-003 in DMD. The company expects key catalysts in mid-2026: potential FD
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Compan
Solid Biosciences (NASDAQ:SLDB) Director Sells $46,400.20 in Stock
06:18am, Monday, 09'th Feb 2026
Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) Director Ilan Ganot sold 7,205 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at a
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
08:00am, Friday, 06'th Feb 2026
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:46pm, Tuesday, 13'th Jan 2026
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomod
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expect
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment
